These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2554626)

  • 21. Cell-mediated immunity in herpes simplex virus-infected mice: induction, characterization and antiviral effects of delayed type hypersensitivity.
    Nash AA; Field HJ; Quartey-Papafio R
    J Gen Virol; 1980 Jun; 48(Pt 2):351-7. PubMed ID: 6249885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection from herpes simplex virus type 2 is associated with T cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes on glycoprotein D.
    Wachsman M; Luo JH; Aurelian L; Paoletti E
    Vaccine; 1992; 10(7):447-54. PubMed ID: 1376951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to vaginal or systemic infection with herpes simplex virus type 2.
    Breinig MC; Wright LL; McGeorge MB; Morahan PS
    Arch Virol; 1978; 57(1):25-34. PubMed ID: 207239
    [No Abstract]   [Full Text] [Related]  

  • 24. Induction of herpes simplex virus immunity in newborn mice.
    Koyama H; Kasahara S
    Infect Immun; 1975 Dec; 12(6):1472-4. PubMed ID: 173657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and stability of herpes simplex virus antigens in Salmonella typhimurium.
    Bowen JC; Reddy RM; Alpar HO; Brown MR; Rouse BT
    Adv Exp Med Biol; 1995; 371B():1543-6. PubMed ID: 7502853
    [No Abstract]   [Full Text] [Related]  

  • 26. [Immunity to tumors induced by herpes simplex virus in hamsters].
    Kosiakov PN; Posevaia TA; Kosiakova NP; Barinskiĭ IF
    Vopr Virusol; 1991; 36(1):40-4. PubMed ID: 1650065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.
    Roberts PL; Duncan BE; Raybould TJ; Watson DH
    J Gen Virol; 1985 May; 66 ( Pt 5)():1073-85. PubMed ID: 2582080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of keratinocytes in human recurrent herpetic lesions. Ability to present herpes simplex virus antigen and act as targets for T lymphocyte cytotoxicity in vitro.
    Cunningham AL; Noble JR
    J Clin Invest; 1989 Feb; 83(2):490-6. PubMed ID: 2464000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerance and immunity in mice infected with herpes simplex virus: simultaneous induction of protective immunity and tolerance to delayed-type hypersensitivity.
    Nash AA; Gell PG; Wildy P
    Immunology; 1981 May; 43(1):153-9. PubMed ID: 7251047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection of mice against herpes simplex virus infection by a Lactobacillus casei preparation (LC 9018) in combination with inactivated viral antigen.
    Watanabe T; Saito H
    Microbiol Immunol; 1986; 30(2):111-22. PubMed ID: 3012292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Herpes simplex virus vaccines.
    Meignier B; Roizman B
    Antiviral Res; 1985; Suppl 1():259-65. PubMed ID: 3002260
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of immunosuppression on recurrent herpes simplex in mice.
    Blyth WA; Harbour DA; Hill TJ
    Infect Immun; 1980 Sep; 29(3):902-7. PubMed ID: 6253401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clonal analysis of T-cell responses to herpes simplex virus: isolation, characterization and antiviral properties of an antigen-specific helper T-cell clone.
    Leung KN; Nash AA; Sia DY; Wildy P
    Immunology; 1984 Dec; 53(4):623-33. PubMed ID: 6209206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of "modified-self"-induced specific antibody hyporesponsiveness to herpes simplex virus.
    Wilson LA; Thompson JJ; Ohkawa S; Scott DW
    Viral Immunol; 1992; 5(2):113-22. PubMed ID: 1377470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
    Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
    Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Murine cytotoxic T lymphocytes specific for herpes simplex virus type 1 recognize the immediate early protein ICP4 but not ICP0.
    Martin S; Zhu XX; Silverstein SJ; Courtney RJ; Yao F; Jenkins FJ; Rouse BT
    J Gen Virol; 1990 Oct; 71 ( Pt 10)():2391-9. PubMed ID: 2172452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection against ocular and cutaneous infection with herpes simplex virus type 1 by intragastric immunization with live virus.
    Irie H; Shimeld C; Williams N; Hill T
    J Gen Virol; 1993 Jul; 74 ( Pt 7)():1357-62. PubMed ID: 8393076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2.
    McDermott MR; Brais LJ; Evelegh MJ
    J Gen Virol; 1990 Jul; 71 ( Pt 7)():1497-504. PubMed ID: 2165134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell-mediated immunity to herpes simplex virus in man.
    Russell AS
    Am J Clin Pathol; 1973 Dec; 60(6):826-30. PubMed ID: 4357123
    [No Abstract]   [Full Text] [Related]  

  • 40. Prevention of herpes simplex virus diseases in man.
    Epstein JS; Quinnan GV
    Clin Dermatol; 1984; 2(2):133-46. PubMed ID: 6100714
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.